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in Aortic Stenosis*Jonathon M. White, MD, Susheel K. Kodali, MDSEE PAGE 1346A trial ﬁbrillation (AF) is well established as animportant predictor of risk across a broadspectrum of cardiac disease. An association
with increased mortality has been demonstrated in
ischemic heart disease, heart failure, and valvular
disease (1–5). In addition, AF is a common problem
following surgical aortic valve replacement (SAVR)
where it has been associated with increased adverse
events, including mortality (6). What remains un-
known is whether this association between AF and
adverse events reﬂects a direct causal role or rather
a marker for more advanced cardiac disease.
Transcatheter aortic valve replacement (TAVR) is
currently accepted as an alternative to SAVR for pa-
tients with aortic stenosis at high surgical risk, with
emerging data now suggesting improved outcomes
with TAVR in this population (7). Recently, studies in
intermediate-risk patients have demonstrated excel-
lent early outcomes (8). Ongoing randomized clinical
trials will answer whether TAVR will become the
preferred therapy in lower-risk patients. Randomized
trials have demonstrated that AF rates are higher af-
ter SAVR compared with TAVR (30.5% vs. 11.7% at 30
days in CoreValve US Pivotal Trial and 16.0% vs. 8.6%
in PARTNER A [Placement of Aortic Transcatheter
Valve Trial]), and it is possible that reduced AF burden*Editorials published in JACC: Cardiovascular Interventions reﬂect the
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tents of this paper to disclose.is playing a role in the improved late outcomes with
TAVR (7,9). However, there is still a paucity of data
examining the role that AFmight play following TAVR,
limited to a few small studies with conﬂicting results
(10–12). As such, the ability to tease out the impor-
tance of AF in this clinical setting has been limited.In this issue of JACC: Cardiovascular Interventions,
the study by Chopard et al. (13) represents the largest
study to date documenting the relationship between
AF and clinical outcomes following TAVR. The in-
vestigators’ retrospective analysis comes from the
FRANCE 2 (French Transcatheter Aortic Valve Inter-
vention Registry), using the data of almost 4,000
inoperable patients treated in 33 centers. The study
used 12-lead electrocardiograms obtained during in-
hospital follow-up to deﬁne patients as having pre-
existing AF, new-onset AF, or no AF. Pre-existing AF
was shown to be extremely common in inoperable
patients undergoing TAVR—25.8% in this study. In
those without established AF, the ﬁnding of newly
documented AF was less common—6% of the remain-
ing patients. The investigators analyzed the impact
of pre-existing and new-onset AF independently.
Patients with pre-existing AF were older, had more
comorbidities, worse left ventricular function, and
more paravalvular leak after TAVR. When compared
with patients without documented AF, no difference
in adverse events at 30-day follow-up was seen.
However, at 1 year, a signiﬁcant increase in all-cause
mortality was noted in those with AF (26.5% vs.
16.6%), as well as worse heart failure symptoms and a
higher rate of rehospitalization. Importantly, no dif-
ferences in stroke or major bleeding were observed;
however, an important limitation of this study is that
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Patients with new-onset AF were older but not
obviously more comorbid than those in whom AF was
not observed. However, they were treated more
frequently by nontransfemoral access routes and
were more likely to suffer procedure-related adverse
events, suggesting that underlying comorbidity is
likely. At both 30-day and 1-year follow-up, those
with new AF had an increase in adverse events,
including all-cause mortality at 1 year (20.7% vs.
11.1%).
On multivariate analysis, both pre-existing AF
(odds ratio [OR]: 1.72) and newly documented AF af-
ter TAVR (OR: 1.79) were shown to be among the
strongest independent predictors of all-cause 1-year
mortality with odds similar to paravalvular leak and
chronic kidney disease. This observation was consis-
tent across almost all subgroups on further analysis.
The present study is important and has many
strengths as it is the ﬁrst, large registry-based anal-
ysis to describe the scope of the AF problem and its
potential role in modifying risk in inoperable TAVR
patients. Many questions remain however. Although
AF appears to be an important independent predictor
of risk, whether AF truly modiﬁes risk in these pa-
tients or merely reﬂects other comorbidity and worse
heart failure is impossible to know. Indeed, the in-
vestigators surmise that worse heart failure might
drive the worse outcomes observed in AF patients. In
this study, patients with pre-existing AF were sicker,
had more incidences of heart failure, and worse par-
avalvular leak. Patients with new AF were more likely
to have undergone a nontransfemoral approach, an
intuitive cause of AF as well as a reﬂection of a more
comorbid population with more extensive vascular
disease. Although multivariate models can suggest
that AF is problematic in and of itself, knowing this
for sure is not possible and requires further study.
Data supporting improved outcomes from the resto-
ration or maintenance of sinus rhythm in the general
population are lacking and whether such strategies
might beneﬁt TAVR patients is not known.
Two major limitations of this study warrant men-
tion. Although no differences in stroke or bleeding
outcomes were noted, the interaction among stroke,bleeding, and antithrombotic therapy is complex and
data on the use of these medications might further
inform the reported results. New-onset AF was
deﬁned by analysis of a single 12-lead electrocardio-
gram, without the use of continuous telemetry. A
recent study by Urena et al. (14) found asymptomatic
arrhythmias to be common immediately before TAVR
(6.4% had asymptomatic new AF) and found that the
discovery of new arrhythmias was highly likely to
alter patient management. Asymptomatic AF is a
common problem, so it seems likely that the burden of
new AF is underestimated in the present study,
although whether short, asymptomatic episodes of
AF are prognostically important remains unclear.
Furthermore, no data are available regarding patient
rhythm at discharge. Not only does sustained AF at
discharge have important implications for patient
management, it might also portend a clinical course
that is different to patients with short, paroxysmal
episodes of AF following a procedure. The impact of
the exclusion of 251 patients who died in-hospital
before follow-up is not known but the lack of elec-
trocardiogram data on these patients could have
affected the overall results.
Finally, whether treatment directed speciﬁcally at
AF might improve clinical outcomes remains unclear.
The relationship between AF, heart failure, and pro-
cedural outcomes including stroke and bleeding is
a complex one. What is clear, however, is that inop-
erable patients with AF carry a large burden of car-
diovascular disease and should be considered for
comprehensive heart failure and antithrombotic
treatment, all directed at reducing the long-term
consequences of heart failure even after relief of
valvular obstruction from aortic stenosis. The study
by Chopard et al. (13) highlights the importance of
AF and heart failure both before and after TAVR and
the need for further studies concerning the AF and
heart failure–speciﬁc management of this patient
population.
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